

RESEARCH Open Access



Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells

1, 2, 3, 4, 1*, 2*

Abstract

Background: Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells.

Results: The essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. The essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells.

Conclusions: The essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells.

Keywords: Essential amino acid ratio, mTOR, lipogenic gene network, miRNA expression, bovine mammary epithelial cells.

Background

Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells.

Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells.

Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells. Essential amino acid ratio and mTOR affect lipogenic gene network and miRNA expression in bovine mammary epithelial cells.

6 1 4 -B 1
AA
1 (C1) 9 .
C
AA A , -
5-7 . , C -
AA C1 -
A - B -1
10 -
AA . , -

AA,

A () -80 C . A D A
 A . D A
 100 A, 1 μ
 A - (, B ,), 9 μ
 65 C 5
 4 , 4 -
 1, (/ - 3 . A 9 μ , 4 μ
), 5 - B (,), 1 μ
 6 -1, 1 (18, 2 μ 10 / 5'-
). 0 - (), 0.25 μ
 1.625 μ (),
 D A (9.1, A , , :
 C , C) A , , 25 C 5 , 42 C 60 , 70 C 5 .
 A C D A 1:4
 (0, 1,
 6, 12), (- AA, AA C, C
 AA), () 384-
 12- A .C , (, (A B , C ,
 D A , 6 μ
 5 μ 1 B
 , D), 0.4 μ 10 μ /
 , 0.2 μ 6-

M, e p e i e

AB
 - 7900 D (A B)
 : 5 95 C, 40
 1 95 C, 30 60 C.
 50- C
 75 2 37 C . 65 C 15 , 95 C 15 . D
 7900 D
 (2.4, A B).

B (, 18 . A -
 , (24) 2 C
 ≥ 90 % . , A 1: 1.
 AA, C
 AA C, 2.1, 1.3, 3.0, 1.6 “ A 13 . C
 ”
 (. , 3) (GADPH, UXT, RPS9)
 12 . 21 . D A (9.1, A
 , C , C)
 A (-)
 (AA C).
 (n=3 /).

NAe
 A (, , CA). C -
 D D (n=3 /).
 D-1000 (D , -
 , D). A ()
 A 2100 B (A , D A -
 C , CA). 7.5. A -
 A 100 /μ - P<0.05.
 D

Results

Gene expression of FA metabolism-related genes in the liver of sheep. The expression levels (fold change) of various genes were measured. Significant differences (P < 0.05) are indicated by different letters (A, B, C) above the bars. P-values for comparisons between treatments are provided in parentheses.

FA activation and Intra-cellular transport

- ACSL1**: 1 (ACSL1) (P < 0.01)
- ACSS2**: 2 (ACSS2) (P < 0.01), 3 (ACSS2) (P < 0.01)
- FABP3**: 1 (FABP3) (P < 0.01), 2 (FABP3) (P < 0.01), 3 (FABP3) (P < 0.01)

De novo FA synthesis and desaturation


- ACACA**: 1 (ACACA) (P < 0.01), 2 (ACACA) (P < 0.01), 3 (ACACA) (P < 0.01)
- FASN**: 1 (FASN) (P < 0.01), 2 (FASN) (P < 0.01), 3 (FASN) (P < 0.01)
- SCD**: 1 (SCD) (P < 0.01), 2 (SCD) (P < 0.01), 3 (SCD) (P < 0.01)

Triacylglycerol synthesis

- AGPAT6**: 1 (AGPAT6) (P < 0.01), 2 (AGPAT6) (P < 0.01), 3 (AGPAT6) (P < 0.01)
- DGAT1**: 1 (DGAT1) (P < 0.01), 2 (DGAT1) (P < 0.01), 3 (DGAT1) (P < 0.01)
- LPIN1**: 1 (LPIN1) (P < 0.01), 2 (LPIN1) (P < 0.01), 3 (LPIN1) (P < 0.01)

Regulation of transcription

- INSIG1**: 1 (INSIG1) (P < 0.01), 2 (INSIG1) (P < 0.01), 3 (INSIG1) (P < 0.01)
- SREBF1**: 1 (SREBF1) (P < 0.01), 2 (SREBF1) (P < 0.01), 3 (SREBF1) (P < 0.01)
- PPARG**: 1 (PPARG) (P < 0.01), 2 (PPARG) (P < 0.01), 3 (PPARG) (P < 0.01)
- PPARD**: 1 (PPARD) (P < 0.01), 2 (PPARD) (P < 0.01), 3 (PPARD) (P < 0.01)
- RXRA**: 1 (RXRA) (P < 0.01), 2 (RXRA) (P < 0.01), 3 (RXRA) (P < 0.01)
- NR1H3**: 1 (NR1H3) (P < 0.01), 2 (NR1H3) (P < 0.01), 3 (NR1H3) (P < 0.01)



($P < 0.01$). C

AA, 2.1, 1.3, 3.0 1.6 ($P < 0.01$).
 , AA 2.1,
 1.3, 3.0 1.6 ($P < 0.01$).
 (RXRA) -
 AA ($P = 0.01$) - 1.6 ($P < 0.01$)
 .
 α (NR1H3) - ($P < 0.01$) 2.1,
 1.3, 3.0 1.6 ,
 1.6 ($P < 0.01$) 2.1,
 1.3 3.0.

M NAe p e ,
 A -
 . 2. , 2
 7 A -
 (. 2). C AA ,
 21 ($P < 0.01$) -
 2.1, 1.3, 3.0 1.6.
 1.6 ($P < 0.01$)
 21 2.1, 1.3 3.0 C -
 27AB
 ($P < 0.01$) , AA, 2.1, 1.3
 3.0, 1.6

Discussion

l i e e i g - , l - l l - p i g , i g e e

24 . C 24 CA - 1
 ACSS2, FABP3, SCD, LPINI 31 , .
 SREBF1 - .
 A . , , -
 - SREBF1 AA - PPARG 32 . , -
 A A . A γ 13 . A (α, δ, γ) -
 SREBF1, C1 . 25 (1) C, , (C A) -
 , B 1. , 19 33 . A -
 , A 26 . , (ACACA, FASN), A (AGPAT6, DGAT1, -
 LPINI (SREBF1, INSIG1) A () .
 , A D PPARG, -
 . B AA C AA AA
 , A A A
 A 33 . . 34
 - α (NR1H3), A PPARG A .
 (RXRA) SREBF1, FASN, -α (NR1H3) A / -
 SCD ACACA 27 . - -α (NR1H3) A
 C A 0901317 28 . PPARGCIA LPINI A -
 D 1 3, C1 13 . , -
 - -α. , 1 3 , - RXRA PPARD A -
 AA AA C - (ACACA, FASN), (SCD), -
 1 3 , NR1H3 - A (FABP3), -
 RXRA 29 . , - - PPARD 35 . -
 , SREBF1 35 .
 1 3 A AA ,
 - NR1H3 AA, (ACACA, FASN, SCD)
 A (ACACA FASN) AA AA -
 (SCD) SREBF1 INSIG1. (. . FASN, SREBF1) AA
 SCD A . 30 , SREBF1- AA 11, 36 . , FASN
 - 30 . , - SREBF1 AA
 INSIG1, B 1, - C 36 . D

, ,

B - FASN 13 .

- 37 , . .

, (1 A 1),

38 , . .
. A

(. .)

38 .

e.g. - ' | - | | - 2 19 ' 19 e b e p e . .
- ' EAA
Lys to Thr ratios

6 1 9 . C , A -
A . 7

. ,

PPARG

130A
130B.

PPARG *PPARG*-A A

A. AA AA C

130A AA AA C

27AB 130A, 21

47 .

21 B 1- 53

48 . , *SREBF1* 47,

2.1, 1.3, 3.0, 21 *SREBF1*

A , 1.6 *SREBF1*

2.1, 1.3 21

B 1 48 . , AA B 1- 53-

27AB, 130A 21

. D AA

34A; 45 , A (103, 378,

A

(D) 49 . B A

7 A

(-199 , -199 -3 , -98, -378, -148

-21-5) , 1 (-200)

AA

A

AA

Additional file

Additional file 1: Table S1.

1 (18)

Abbreviations

1, 2, -3- 1, 4, 1, 6, 1- 4 - 1, 3- 1, 1, 103, 103 130, 130, 21, 21, 21, 27, 27, 34, 34, 378, 378, 448, 448 (/) 1, 1, 3, 6 1, 6 -1 9, 1, 1, 1

Additional file 1


()

Figure

2011 100801). (-538-914 ...)

Additional file 1


Additional file 1



Additional file 1

Additional file 1

Conclusions



Received: 23 December 2015 Accepted: 19 July 2016
 Published online: 03 August 2016

1. ...
 2. ... 2012 98 3951-68.
 3. ... 124. 2007. 587-8.
 4. ... 2006 89 1 1-14.
 5. ... 2011 141 1209-15.
 6. ... 2012 142 484-91.
 7. ... () ... 2014 97 419-29.
 8. ... 2014 97 1047-56.
 9. ... () ... 2016 10.3168/2015-10591.
 10. ... 6 1 2008 105 1038-47.
 11. ... 2008 8 224-36.
 12. ... 2011 141 75-80.
 13. ... 2002 269 3742-50.
 14. ... 2008 9 366.
 15. ... -27 ... 2009 390 247-51.
 2011 236 997-1004.

16. ... Y 3 3-1 ... 2012 40 4446-60.
 17. ... -21 ... 1- 53- 1 ... 2015. 10.1136/2014-308430.
 18. ... 2008 582(1) 90-6.
 19. ... () ... 978-953-51-0944-0, 2013 10.5772/51357.
 20. ... 2009 92 4276-89.
 21. ... 2012 95 6042-56.
 22. ... 2013 96 420-30.
 23. ... 2007 29 312-9.
 24. ... - 70 6 -1
 25. ... 2009 49 1913-25.
 26. ... 2010 107 3441-6.
 27. ... 2012 95 3743-55. -1.
 28. ... 1 1 ... 2011 146 408-20. ()
 29. ... 2010 93 4651-8.
 30. ... 1995 9 1033-45.
 31. ... 2013 96 112-21. 1
 32. ... 2007 41 401-27.
 33. ... 2004 134 2444 -9.
 34. ... 2013 684159. 10.1155/2013/684159
 35. ... Y- ... 2012 53 1117-25.
 36. ... 2013 7 1508-16.
 37. ... 2010 39 801-10.
 2005 135 249-502.

38. 2011 583-98.

39. 2005 21 1052-8.

40. 2013 8, 79258. ... -103

41. ... -373

42. 2008 105 1608-13.

43. 2007 318 1931-4.

44. 2005 120 15-20. ... -27

45. 2013 521 15-23. 2011. ... -130 2011 31

46. 626-38. ... 130 -

47. 2015 10, 0142809. ... -21

48. ... 1- 53- 1 ... 2015 10.1136/ ... -2014-308430. ... 53

49. 2013 5 147-1450. 2015 16 884.

S b a c B M C a
a a :

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

